D-Index & Metrics Best Publications

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 105 Citations 44,068 733 World Ranking 3961 National Ranking 189

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Gene
  • Cancer

Dieter Hoelzer mainly investigates Internal medicine, Acute lymphocytic leukemia, Immunology, Surgery and Oncology. Internal medicine connects with themes related to Gastroenterology in his study. His research in Acute lymphocytic leukemia intersects with topics in Survival rate, Philadelphia chromosome, Imatinib, Induction chemotherapy and Acute leukemia.

His work deals with themes such as Cancer research and Haematopoiesis, which intersect with Immunology. His studies deal with areas such as Pharmacotherapy, Immunophenotyping and Cohort as well as Oncology. In his research on the topic of Leukemia, Myeloid is strongly related with Myeloid leukemia.

His most cited work include:

  • Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI) (2129 citations)
  • Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL (1118 citations)
  • Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. (1020 citations)

What are the main themes of his work throughout his whole career to date?

His primary areas of study are Internal medicine, Immunology, Cancer research, Oncology and Leukemia. His Internal medicine research includes themes of Gastroenterology and Surgery. His Immunology research is multidisciplinary, incorporating perspectives in Haematopoiesis and Stem cell.

His research investigates the connection between Oncology and topics such as Minimal residual disease that intersect with issues in Adult Acute Lymphoblastic Leukemia. His research integrates issues of Myeloid, Molecular biology and BAALC in his study of Leukemia. His work carried out in the field of Acute lymphocytic leukemia brings together such families of science as Survival rate and Philadelphia chromosome.

He most often published in these fields:

  • Internal medicine (43.46%)
  • Immunology (31.10%)
  • Cancer research (19.04%)

What were the highlights of his more recent work (between 2009-2020)?

  • Internal medicine (43.46%)
  • Oncology (17.88%)
  • Transplantation (15.12%)

In recent papers he was focusing on the following fields of study:

The scientist’s investigation covers issues in Internal medicine, Oncology, Transplantation, Acute lymphocytic leukemia and Minimal residual disease. His studies deal with areas such as Gastroenterology, Surgery and Immunology as well as Internal medicine. His research investigates the connection between Immunology and topics such as Cancer that intersect with problems in Disease.

Dieter Hoelzer combines subjects such as Lymphoblastic Leukemia and Rituximab with his study of Oncology. His Transplantation research is multidisciplinary, relying on both Stem cell, Pediatrics, Phases of clinical research and Dasatinib. His work deals with themes such as Survival rate, Blinatumomab and Clinical trial, which intersect with Acute lymphocytic leukemia.

Between 2009 and 2020, his most popular works were:

  • Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial (865 citations)
  • Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival (696 citations)
  • Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease (602 citations)

In his most recent research, the most cited papers focused on:

  • Gene
  • Internal medicine
  • Cancer

Dieter Hoelzer mainly focuses on Internal medicine, Acute lymphocytic leukemia, Transplantation, Immunology and Oncology. The study incorporates disciplines such as Gastroenterology and Surgery in addition to Internal medicine. His study looks at the intersection of Acute lymphocytic leukemia and topics like Blinatumomab with T cell and Molecular Response.

His Transplantation research includes elements of Cytarabine and Retrospective cohort study. His work on Immunodeficiency as part of general Immunology study is frequently linked to Centrosome duplication, bridging the gap between disciplines. His Hematopoietic stem cell transplantation research incorporates elements of Chemotherapy and Minimal residual disease.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI)

Birgit Assmus;Volker Schächinger;Claudius Teupe;Martina Britten.
Circulation (2002)

3188 Citations

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.

Hagop M Kantarjian;Francis Giles;Lydia Wunderle;Kapil Bhalla.
The New England Journal of Medicine (2006)

1593 Citations

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Mathias J Rummel;Norbert Niederle;Georg Maschmeyer;G Andre Banat.
The Lancet (2013)

1527 Citations

Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1.

Marion G Ott;Manfred Schmidt;Kerstin Schwarzwaelder;Stefan Stein.
Nature Medicine (2006)

1309 Citations

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

Max S. Topp;Peter Kufer;Nicola Gökbuget;Mariele Goebeler.
Journal of Clinical Oncology (2011)

1164 Citations

Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease

Stefan Stein;Marion G. Ott;Stephan Schultze-Strasser;Anna Jauch.
Nature Medicine (2010)

827 Citations

Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults

D Hoelzer;E Thiel;H Loffler;T Buchner.
Blood (1988)

748 Citations

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

Oliver G. Ottmann;Brian J. Druker;Charles L. Sawyers;John M. Goldman.
Blood (2002)

708 Citations

Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia.

Monika Brüggemann;Thorsten Raff;Thomas Flohr;Nicola Gökbuget.
Blood (2006)

611 Citations

Modern Therapy of Acute Lymphoblastic Leukemia

Renato Bassan;Dieter Hoelzer.
Journal of Clinical Oncology (2011)

590 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Dieter Hoelzer

Hagop M. Kantarjian

Hagop M. Kantarjian

The University of Texas MD Anderson Cancer Center

Publications: 347

Jorge E. Cortes

Jorge E. Cortes

Augusta University

Publications: 222

Elias Jabbour

Elias Jabbour

The University of Texas MD Anderson Cancer Center

Publications: 159

Susan O'Brien

Susan O'Brien

University of California, Irvine

Publications: 153

Arnold Ganser

Arnold Ganser

Hannover Medical School

Publications: 115

Farhad Ravandi

Farhad Ravandi

The University of Texas MD Anderson Cancer Center

Publications: 104

Adrian J. Thrasher

Adrian J. Thrasher

University College London

Publications: 98

Axel Schambach

Axel Schambach

Hannover Medical School

Publications: 98

Oliver G. Ottmann

Oliver G. Ottmann

Cardiff University

Publications: 87

Stefanie Dimmeler

Stefanie Dimmeler

Goethe University Frankfurt

Publications: 83

Giovanni Martinelli

Giovanni Martinelli

University of Bologna

Publications: 79

Christopher Baum

Christopher Baum

Charité - University Medicine Berlin

Publications: 78

Andreas Hochhaus

Andreas Hochhaus

Friedrich Schiller University Jena

Publications: 76

Hervé Dombret

Hervé Dombret

Université Paris Cité

Publications: 76

Mark R. Litzow

Mark R. Litzow

Mayo Clinic

Publications: 76

Michele Baccarani

Michele Baccarani

University of Bologna

Publications: 73

Trending Scientists

Jeng-Shyang Pan

Jeng-Shyang Pan

Shandong University of Science and Technology

Furu Wei

Furu Wei

Microsoft (United States)

Kevin R. Wilson

Kevin R. Wilson

Lawrence Berkeley National Laboratory

David D. Kitts

David D. Kitts

University of British Columbia

Ulrich G. Mueller

Ulrich G. Mueller

The University of Texas at Austin

Catherine E. Dewey

Catherine E. Dewey

University of Guelph

Eduardo Caruso Machado

Eduardo Caruso Machado

Instituto Agronômico de Campinas

Konstantinos T. Konstantinidis

Konstantinos T. Konstantinidis

Georgia Institute of Technology

Roscoe O. Brady

Roscoe O. Brady

Beth Israel Deaconess Medical Center

Michael Nothnagel

Michael Nothnagel

University of Cologne

Mark C. Jenkins

Mark C. Jenkins

United States Department of Agriculture

Jeanne L. Nel

Jeanne L. Nel

Nelson Mandela University

Gian Domenico Iannetti

Gian Domenico Iannetti

University College London

Timothy J. Trull

Timothy J. Trull

University of Missouri

Graeme I. Murray

Graeme I. Murray

University of Aberdeen

C.P. Burgess

C.P. Burgess

Perimeter Institute

Something went wrong. Please try again later.